Affordable Access

[Efficacy of vinorelbine monotherapy in advanced and metastatic breast cancer].

Authors
  • Suehisa, Hiroshi
  • Aogi, Kenjiro
  • Hara, Fumikata
  • Takabatake, Daisuke
  • Takashima, Seiki
  • Ohsumi, Shozo
  • Takashima, Shigemitsu
  • Komatsubara, Kazuo
Type
Published Article
Journal
Gan to kagaku ryoho. Cancer & chemotherapy
Publication Date
Oct 01, 2008
Volume
35
Issue
10
Pages
1709–1712
Identifiers
PMID: 18931573
Source
Medline
License
Unknown

Abstract

Vinorelbine is a newanti-cancer drug that is available for advanced or metastatic breast cancer, approved by the Japanese Ministry of Health, Labour and Welfare in May 2005. At present, we evaluated the efficacy and safety of vinorelbine in our hospital. 51 patients were treated with vinorelbine since April 1, 2006 to August 20, 2007. Average age was 55.9 years old and period of treatment was 161.9 days. Average number of previous treatments was 2.2, and 37 patients(72.6%)were treated with anthracyclines and taxanes. The response rate was 19.6%, there was one complete responder, and nine partial responders. Especially, the response rate was 16.2% in patients pretreated with anthracyclines and taxanes. The major toxicity was grade 3 or 4 neutropenia(15.7%), and superficial phlebitis(7.8%). Vinorelbine will be a standard treatment agent for patients pretreated with anthracyclines and taxanes.

Report this publication

Statistics

Seen <100 times